Cogent Biosciences' Q2 net loss widens as costs mount

Cogent Biosciences

05/08/2025 13:14

Overview

Cogent Q2 net loss widens to $73.5 mln from nearly $59.0 mln yr ago

Bezuclastinib shows statistically significant results in SUMMIT trial

Co's cash position expected to fund operations through 2027, including launch

Outlook

Company projects cash runway into 2027

Result Drivers

R&D COSTS: R&D expenses increase mainly due to costs incurred to support on-going SUMMIT, PEAK and APEX clinical trials

FINANCIAL POSITION - Cogent's cash position, strengthened by a recent public offering, is expected to support operations through 2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$73.53 mln
Q2 Income from Operations
-$75.58 mln
Q2 Operating Expenses
$75.58 mln


Press Release: ID:nGNX6VtWgC

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)